| Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study. | |
| | |
MedLine Citation:
|
PMID: 12548230 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Mebendazole is an anthelmintic that is commonly needed in women of reproductive age. Its use in pregnancy is a reason for concern for women and their health care providers. The purpose of this study was to examine the fetal safety of mebendazole. STUDY DESIGN: The Israeli Teratogen Information Service prospectively collected and followed 192 pregnancies exposed to mebendazole in pregnancy, 71.5% of whom had first-trimester exposure. Pregnancy outcome was compared with that of a matched control group, who were counseled for nonteratogenic exposure. RESULTS: There was no increase in the rate of major malformations between the groups (5/150 pregnancies [3.3%; mebendazole] vs 3/175 pregnancies [1.7%; nonteratogenic control subjects]; P =.478). There was a higher rate of elective terminations of pregnancy in the exposed group compared with the control group (22/192 pregnancies [11.5%; mebendazole] vs 3/192 pregnancies [1.6% [nonteratogenic control subjects]; P =.000). CONCLUSION: This study suggests that mebendazole does not represent a major teratogenic risk in humans when it is used in the doses that are used commonly for pinworm (Enterobius vermicularis) infestation. |
| | |
Authors:
|
Orna Diav-Citrin; Svetlana Shechtman; Judy Arnon; Israela Lubart; Asher Ornoy |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of obstetrics and gynecology Volume: 188 ISSN: 0002-9378 ISO Abbreviation: Am. J. Obstet. Gynecol. Publication Date: 2003 Jan |
Date Detail:
|
Created Date: 2003-01-27 Completed Date: 2003-02-20 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0370476 Medline TA: Am J Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 282-5 Citation Subset: AIM; IM |
Affiliation:
|
Israeli Teratogen Information Service, Israel Ministry of Health, Jerusalem, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abnormalities, Drug-Induced
/
epidemiology* Abortion, Induced / statistics & numerical data Adult Antinematodal Agents / adverse effects* Birth Weight Cohort Studies Enterobiasis / drug therapy Female Gestational Age Humans Maternal-Fetal Exchange Mebendazole / administration & dosage, adverse effects* Pregnancy Pregnancy Outcome* Prospective Studies Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antinematodal Agents; 31431-39-7/Mebendazole |
| Comments/Corrections | |
Comment In:
|
Am J Obstet Gynecol. 2003 Jan;188(1):5-6
[PMID:
12548188
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Placenta previa in singleton and twin births in the United States, 1989 through 1998: a comparison o...
Next Document: Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials.